Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?-Reference-Cited by-同舟云学术

Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?

Published:2019-05 Issue:13 Volume:15 Page:1505-1524
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Hindy Joya-Rita¹,Souaid Tarek¹,Kourie Hampig Raphael¹²,Kattan Joseph²

Affiliation:

1. Medical Genetics Unit, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

2. Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

Abstract

Bladder cancer (BC) is the most frequent cancer affecting the urinary tract. With the growing era of targeted therapies around the 2000s, many trials evaluated the efficacy of targeted therapy in advanced BC. However, no approval was given yet to any form of targeted therapy when it comes to BC. The aim of this paper was to report the most pivotal trials that evaluated different families of targeted therapy in the treatment of BC, according to their biomarkers (FGFR3, EGFR, HER2, VEGF and PI3K/AKT/mTOR). The ongoing trials testing targeted therapies in advanced BC were then summarized. Finally, the different immunotherapies approved for this disease and their potential combination with targeted therapy were addressed.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0459

Reference109 articles.

1. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

2. Genetic susceptibility to bladder cancer risk and outcome

3. HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome

4. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-Temperature/pH-Sensitive Hydrogels with Excellent Strength and Toughness Crosslinked Using Three Crosslinking Methods;Gels;2024-07-19

2. RFWD3 acts as a tumor promotor in the development and progression of bladder cancer;HISTOL HISTOPATHOL;2023

3. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer;ESMO Open;2023-06

4. Long Non-Coding RNA and Chemoresistance in Bladder Cancer – A Mini Review;Cancer Investigation;2022-11-14

5. Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single‑center experience;Experimental and Therapeutic Medicine;2022-10-04